Key Highlights
- Fourth-quarter revenue reached $9.7 billion, representing 9.9% year-over-year growth — marking the company’s most robust annual revenue expansion in ten years
- Shares currently valued at 13.5x forward earnings, below the historical 10-year average of 16x and trading at a discount versus competitors including Abbott and Stryker
- Cardiac Ablation Solutions division posted remarkable growth of 78% globally and 124% domestically, capturing significant market position from Boston Scientific
- The Hugo robotic surgical platform offers approximately 40% cost savings compared to Intuitive Surgical’s da Vinci, positioning it in a market anticipated to surpass $54 billion
- Wall Street firms TD Cowen and RBC maintain price objectives of $119 and $118 respectively, suggesting potential gains exceeding 50% from present trading levels
Medtronic (MDT) stock has experienced challenging market conditions over recent years. The medical device leader developed a track record of missing investor expectations, which has been reflected in share price performance. However, the narrative appears to be shifting.
The corporation’s fiscal 2026 fourth-quarter earnings, released on June 3, exceeded analyst projections. Top-line results climbed 9.9% compared to the prior year, reaching $9.7 billion. This propelled full-year expansion to 8.4% — representing the strongest annual revenue performance witnessed in a full decade.
MDT shares currently change hands near $78, significantly below the 52-week peak of $106.33. With a forward earnings multiple of 13.5 and yielding 3.7% in dividends, the valuation appears attractive both historically and relative to industry competitors.
The company’s historical 10-year average forward P/E hovers around 16. Industry peers including Abbott, Boston Scientific, Johnson & Johnson, and Stryker command price-to-sales multiples near 4. Medtronic’s current ratio stands at 2.8.
RBC Capital Markets’ Shagun Singh maintains an Outperform rating alongside a $118 price objective. TD Cowen recently confirmed a Buy rating with a $119 target. Both analysts emphasize the same catalyst: Medtronic stands at the threshold of a significant product innovation cycle.
Cardiac Ablation Drives Momentum
The cardiovascular division represents the highlight performance area. Accounting for approximately 39% of consolidated revenue, this segment expanded 10% year-over-year to $3.8 billion in the most recent quarter.
Within this division, Cardiac Ablation Solutions (CAS) demonstrates exceptional momentum. Sales skyrocketed 78% on a global basis and 124% within the United States market. The operation is expanding at double the overall market growth rate while capturing eight percentage points of additional market share.
This share gain comes directly from Boston Scientific, which acknowledged lost PFA market position when reducing its full-year guidance. Boston Scientific shares have declined 51% year to date.
Medtronic’s competitive advantage stems from being the sole provider offering two FDA-cleared pulsed field ablation platforms: PulseSelect and the Affera System. Affera integrates PFA and radio-frequency technology with comprehensive cardiac mapping capabilities. CEO Geoff Martha indicated the U.S. installed base expanded 40% sequentially during the latest quarter.
Hugo Targets the Surgical Robotics Expansion
Moving beyond cardiology, Medtronic’s Hugo robotic-assisted surgical platform represents one of the most compelling long-term opportunities within the product portfolio.
Hugo secured FDA authorization for urological procedures in 2025. The organization has submitted applications for general surgery and gynecological uses. The system is positioned at roughly 40% below the price point of Intuitive Surgical’s da Vinci platform.
Robotic surgical procedures currently represent under 5% of total surgeries performed. The worldwide market is forecast to expand beyond $54 billion throughout the coming decade.
In the neuroscience division, fourth-quarter sales increased 5%. Medtronic also obtained FDA clearance during the current year for an innovative Stealth AXiS Spine application designed for brain surgery, broadening its AiBLE surgical technology platform.
Regarding renal care, Needham confirmed a Buy rating and $101 price target recently, highlighting Symplicity Spyral sales reaching an annualized run rate of $100 million. Medicare reimbursement commenced in October 2025.
For fiscal 2027, Medtronic projects organic revenue growth between 6.75% and 7.25% with adjusted EPS ranging from $5.90 to $6.00, representing approximately 8% growth from the previous year’s $5.53.
The organization has increased its dividend payment for 49 consecutive years. The present quarterly distribution stands at $0.72 per share.
